We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

67 hedge funds and large institutions have $7M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

762% more call options, than puts

Call options by funds: $181K | Put options by funds: $21K

122% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 9

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 68 → 67 (-1)

74% less capital invested

Capital invested by funds: $27.1M → $7M (-$20.1M)

Holders
67
Holders Change
-1
Holders Change %
-1.47%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
20
Reduced
9
Closed
16
Calls
$181K
Puts
$21K
Net Calls
+$160K
Net Calls Change
-$460K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$13.2M
2
WE
Wealth Effects
Massachusetts
+$2.21M
3
GJL
Gendell Jeffrey L
+$1.76M
4
Osaic Holdings
Osaic Holdings
Arizona
+$707K
5
MWM
Modera Wealth Management
New Jersey
+$394K

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$1.34M
2
MCM
MAI Capital Management
Ohio
-$935K
3
EWA
EP Wealth Advisors
California
-$206K
4
Millennium Management
Millennium Management
New York
-$184K
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$141K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
51
Victory Capital Management
Texas
$2.5K +$4.29K +1 +33%
MI
52
Moneywise Inc
Virginia
$2.34K +$12.9K +3 New
KAS
53
Kestra Advisory Services
Texas
$2.32K +$12.9K +3 New
Fidelity Investments
54
Fidelity Investments
Massachusetts
$2.23K – – –
CWM
55
Centric Wealth Management
Illinois
$2.12K +$12.9K +3 New
CAG
56
Curtis Advisory Group
California
$2.06K – – –
First Manhattan
57
First Manhattan
New York
$2.06K – – –
ACI
58
Alpha Cubed Investments
California
$2.02K – – –
EWA
59
EP Wealth Advisors
California
$1.84K -$206K -48 -94%
Hudson Bay Capital Management
60
Hudson Bay Capital Management
Connecticut
$1.84K +$12.9K +3 New
NFSG
61
Newbridge Financial Services Group
Florida
$1.1K – – –
SWM
62
Spire Wealth Management
Virginia
$1.05K +$8.57K +2 New
TFGT
63
TS Financial Group (TSFG)
Illinois
$1K – – –
Bank of America
64
Bank of America
North Carolina
$590 – – –
TWC
65
TD Waterhouse Canada
Ontario, Canada
$486 – – –
HCM
66
Hollencrest Capital Management
California
$478 – – –
UBS Group
67
UBS Group
Switzerland
$410 – – –
VWM
68
Venturi Wealth Management
Texas
$295 – – –
IA
69
IFP Advisors
Florida
$219 – – –
National Bank of Canada
70
National Bank of Canada
Quebec, Canada
$189 – – –
BCWM
71
Bartlett & Co Wealth Management
Ohio
$184 – – –
WIM
72
Westside Investment Management
California
$184 – – –
PA
73
Parallel Advisors
California
$156 – – –
FCA
74
FinTrust Capital Advisors
South Carolina
$92 – – –
PNC Financial Services Group
75
PNC Financial Services Group
Pennsylvania
$58 – – –
1 2
3
4

SEEL Hedge Fund Activity: Q3 2023 in Review

67 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2023, worth a combined $7M — down 74% from $27.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SEEL and 15 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 20 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $13.2M. The largest seller was Uniplan Investment Counsel, exiting entirely with an estimated $1.34M sold.

  • 67 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2023, down from 68 in Q2 2023.
  • Funds reported $7M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2023, down 74% quarter-over-quarter.
  • 15 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2023 and 16 closed out, a net change of -1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2023 was Sabby Management, an estimated $13.2M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2023 was Uniplan Investment Counsel, an estimated $1.34M sold.

Based on aggregated 13F filings for Q3 2023.